What will happen to the global stem cell market under the impact of the outbreak?

Read more: The global stem cell therapy market is expected to grow by about $580 million between 2020 and 2024 and is expected to grow at a CAGR of 7%.
2020, the new crown outbreak will have an impact on many industries, but the impact is varied, such as the potential for lower demand in some sectors, but it can also stimulate stable or even faster development in some sectors, while creating encouraging market growth opportunities, such as the outbreak, which has led to higher growth rates in the healthcare industry.
stem cell therapy, which is thought to have led to a new medical revolution, has shown wider application prospects during the outbreak, with several countries launching clinical projects. the impact of the
outbreak has opened up new opportunities for the global stem cell market.
The global stem cell therapy market is expected to grow by about $580 million between 2020 and 2024 and is expected to grow at a CAGR of 7%, according to a report by Technavio, a leading global research firm.
report points out that an important factor driving the growth of the global stem cell therapy market is the growing awareness of stem cell therapy.
upstream: The stem cell storage market is growing at a CAGR of nearly 10% As the demand for personalized drugs in modern medicine continues to rise, more and more people are storing stem cells for future treatments.
According to an analysis by MRFP, an international research firm, the global stem cell storage market is expected to grow at a CAGR of 9.8% between 2019 and 2025 and will exceed $12 billion by 2025.
According to MRFP data, the global stem cell storage market can be divided into neonatal stem cells (cord blood, umbilical cord and placenta), adult stem cells, and embryonic stem cells according to cell type.
according to MRFP analysis, umbilical cord stem cells will maintain the highest market share during the forecast period.
this is similar to the results of a market research report released by Markets and Markets, the world's second-largest market research consultancy, in 2018: the global stem cell storage market is expected to grow fastest.
this is mainly due to the increasing number of placental and umbilical cord storage worldwide and the growing public awareness of the potential for stem cell therapy.
, so it is clear that neonatal stem cell storage has become the mainstream of the stem cell storage market.
Downstream: The clinical demand for stem cells continues to increase, according to Technavio.
the industry perspective section of the Stem Cell Market Size Analysis (2019-2025), published by GRAND VIEW RESEARCH, a U.S. market research firm, has a 300 percent increase in the number of stem cell treatable diseases between 2005 and 2013.
the number of treatable diseases will continue to increase in the future with the help of stem cell technology.
from the downstream clinical application, according to the classification of diseases, the global stem cell treatment market can be divided into thalassemia, cerebral palsy, diabetes, leukemia, autism and so on.
Due to the increased global burden of diabetes, this application may be the fastest growing segment of the market for stem cell therapy, increasing the demand for stem cell therapy.
Nearly 425 million adults worldwide have diabetes in 2017, according to statistics released by the International Diabetes Federation, and are expected to increase to 629 million by 2025.
capital markets have also been very popular in stem cell treatment for diabetes in recent years.
2019 Forta Pharma acquired $950 million to develop diabetes stem cell therapy, San Diego-based diabetes regenerative medicine company ViaCyte received more than $100 million in financing in 2018, and U.S. biotech newcomer Semma Therapeutics raised $114 million in 2017 to develop stem cell therapy for type 1 diabetes.
currently involved in stem cell treatment diabetes research and development worldwide are Athersys, Mesoblast, Caladrius Biosciences, ViaCyte, Sernova, Lilly, Sanofi and Novo Nordisk, and several products are entering the clinical trial phase and getting closer to the market.
thus, the downstream market for stem cell therapy will have greater opportunities in the future.
Industry-wide: The global stem cell market will have a global market capitalization of $270 billion, including upstream and midstream stem cell storage preparation and downstream clinical applications.
According to transparency market research, the global stem cell market is expected to reach $270.5 billion by the end of 2025, and the global stem cell market is expected to grow at a CAGR of 13.8% in the last eight years.
report estimates that a significant increase in the number of clinical applications of stem cells and the emergence of new treatments for chronic diseases will contribute to the growth of the global stem cell market in the coming years.
in addition, the growth of the global stem cell market includes increasing investment in stem cell research projects by biopharmaceutical and pharmaceutical companies, the rapid development of the infrastructure needed for stem cell storage and processing, increased awareness of stem cell treatment diseases, and government-friendly regulation of stem cell diseases.
stem cells are thought to create new opportunities for pharmaceutical companies.
just as in diabetes, pharmaceutical giants such as Lilly, Novo Nordisk and Sanofi, as well as start-ups, are turning to stem cells.
not only develop new stem cell drugs, but pharmaceutical companies can also use stem cell technology to identify candidatedrugs, thereby facilitating the development of new drugs.
, for example, the use of induced pluripotent stem cells to develop human tissue-like organs as disease models for research and development of targeted drugs.
look ahead to 2020, stem cell treatment of new crown pneumonia has achieved phased results, from downstream applications to show the infinite possibilities of stem cell therapy.
at the end of February this year, the Chinese Academy of Sciences science and technology paper pre-release platform (ChinaXiv) published a pre-printed paper on the report of interstitial stem cell venous retransmission treatment of critical patients with new coronary pneumonia clinical patients, patients first return 9 days after transmission, transferred out of the ICU ward, most of the vital signs and clinical trial indicators returned to normal, both throat swabs tested negative for the new coronavirus.
March, the U.S. Bureau of Advanced Biomedical Research and Development (BARDA) evaluated multiStem, a therapeutic stem cell treatment product®, as a treatment highly relevant to the treatment of neo-coronary pneumonia, arguing that it has the potential to significantly improve the lives of patients and potentially be a resource needed to treat neo-coronary pneumonia and other respiratory diseases.
more than a dozen stem cell drugs have been approved for sale worldwide, including knee cartilage deficiency, transplant anti-host disease, Crohn's disease, acute heart attack, hereditary or acquired hematopoietic disease, degenerative arthritis, Heller syndrome, moderate to severe corneal stem cell deficiency, thrombosis arteritis.
with the development of stem cell technology, it will target more extensive indications, the market prospects will be more extensive.
.